GUANGJI PHARMA(000952.SZ)

Company Encyclopedia
View More
name
GUANGJI PHARMA
000952.SZ
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.
3.209 T
000952.SZMarket value -Rank by Market Cap -/-

Financial Score

12/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking210/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-21.62%E
    • Profit Margin-38.62%E
    • Gross Margin29.52%C
  • Growth ScoreD
    • Revenue YoY-10.57%D
    • Net Profit YoY-0.93%C
    • Total Assets YoY-17.01%E
    • Net Assets YoY-20.83%E
  • Cash ScoreD
    • Cash Flow Margin-258.90%D
    • OCF YoY-10.57%D
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreD
    • Gearing Ratio62.67%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The three major A-share indices opened lower collectively, and the precious metals sector weakened

    36Kr learned that the three major A-share indices opened lower collectively, with the Shanghai Composite Index down 0.2%, the Shenzhen Component Index down 0.42%, and the ChiNext Index down 0.63%; the brokerage, retail, and precious metals sectors led the decline, with CLS down 5%, Shanghai Jiubai down over 4%, and Zijin Mining down over 1%; the shipping, pharmaceutical, and internet sectors saw the largest gains, with CMES up over 5%, GUANGJI PHARMA up over 4%, and Yanshan Technology up over 2%

    36Kr·
    SZ
    002945
    +2.58%
    SH
    601872
    +8.85%
    SH
    601899
    +0.11%
    36Kr·
    SZ
    002945
    +2.58%
    SH
    601872
    +8.85%
    SH
    601899
    +0.11%

    Institutions bought 16 stocks including Ingenic today and sold Hi-Tech Spring for 142 million yuan

    According to the data from the Dragon and Tiger List on December 1st, institutions net bought Ingenic, Guoke Technology, and GUANGJI PHARMA, with amounts of 251 million yuan, 147 million yuan, and 77.21 million yuan, respectively. Institutions net sold Hi-Tech Spring, Jereh, and Fibocom, with amounts of 142 million yuan, 128 million yuan, and 85.12 million yuan, respectively

    36Kr·
    SZ
    000952
    0.00%
    SZ
    300638
    +16.54%
    SZ
    300223
    +1.04%
    36Kr·
    SZ
    000952
    0.00%
    SZ
    300638
    +16.54%
    SZ
    300223
    +1.04%

    A-shares closing: The ChiNext index opened lower but rose over 2%, with the consumer sector strengthening in the closing minutes

    The A-shares closed today with the ChiNext Index opening low and rising over 2%, while the consumer sector strengthened towards the end of trading. The Shanghai Composite Index fluctuated within a narrow range throughout the day, closing down 0.15%; the Shenzhen Component Index rose 1.02%; the ChiNext Index increased by 2.14%. Pharmaceutical stocks were strong, with GUANGJI PHARMA and PKU HEALTHCARE hitting the daily limit. CPO and other computing hardware stocks performed well, with Zhongji Xuchuang soaring over 10%. The consumer sector surged towards the end, with GUOGUANG CHAINS and Sanjiang Shopping Club hitting the daily limit. The military industry sector collectively adjusted, with Jiuzhiyang and Jianglong Shipbuilding dropping over 10%. Most individual stocks fell rather than rose, with over 3,500 stocks in the Shanghai, Shenzhen, and Beijing markets showing losses, and the trading volume nearing 1.8 trillion

    Wallstreetcn·
    SZ
    000952
    0.00%
    SZ
    000788
    -0.15%
    SH
    605188
    +1.45%
    Wallstreetcn·
    SZ
    000952
    0.00%
    SZ
    000788
    -0.15%
    SH
    605188
    +1.45%

    GUANGJI PHARMA released its performance for the first three quarters, with a net loss attributable to the parent company of 97.3 million yuan

    According to the Zhitong Finance APP, GUANGJI PHARMA disclosed its third-quarter report for 2025. The company achieved revenue of 429 million yuan in the first three quarters, a year-on-year decrease of 7.12%; the net profit attributable to the parent company was a loss of 97.3 million yuan; the net profit excluding non-recurring gains and losses was a loss of 101 million yuan; basic earnings per share were -0.2789 yuan

    Zhitong·
    SZ
    000952
    0.00%
    Zhitong·
    SZ
    000952
    0.00%

    GUANGJI PHARMA: Net loss of 21.7836 million yuan in the third quarter

    On October 26th, GUANGJI PHARMA announced that in the third quarter of 2025, it achieved operating revenue of 145 million yuan, a year-on-year decrease of 12.57%; the net loss attributable to shareholders of the listed company was 21.7836 million yuan; basic earnings per share were -0.0628 yuan

    Zhitong·
    SZ
    000952
    0.00%
    Zhitong·
    SZ
    000952
    0.00%
    © 2026 Longbridge｜Disclaimer